|
Myopia
|
0.030 |
Biomarker
|
disease |
BEFREE |
In this single-center case series, lenticules were obtained from patients undergoing SMILE for the correction of myopia and the lenticule patch graft was performed in three patients with limbal dermoid.
|
31735992 |
2020 |
|
Myopia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Comparative study of wave-front aberration and corneal Asphericity after SMILE and LASEK for myopia: a short and long term study.
|
30894159 |
2019 |
|
Nasal Type Extranodal NK/T-Cell Lymphoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
<b>Conclusion</b>: Our analysis confirms that SMILE regimen, which is current standard to treat advanced-stage ENKTL may be associated with more severe hematological toxicity compared to other L-asparaginase combinations, including methotrexate-based (AspaMetDex, MESA and MEDA) or gemcitabine-based (GELOX, PGEMOX, DDGP, GDL, GOLD, GLIDE) or CCRT-based regimens.
|
30449214 |
2019 |
|
Myopia
|
0.030 |
Biomarker
|
disease |
BEFREE |
A retrospective case series was conducted at Eye subspecialty center, Cairo, Egypt on 9 eyes with myopia or myopic astigmatism (spherical equivalent - 8.0 and - 12.0D). undergoing SMILE procedure and needed second interference.
|
29454328 |
2018 |
|
Nasal Type Extranodal NK/T-Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
P-glycoprotein is a product of the multidrug resistance (MDR1) gene, which is a major cause of the refractoriness of malignant lymphomas to conventional chemotherapeutic regimens containing anthracycline. l-asparaginase-containing regimens such as SMILE (steroid, methotrexate, ifosfamide, l-asparaginase, and etoposide) are effective for ENKL.
|
23768637 |
2013 |
|
Nasal Type Extranodal NK/T-Cell Lymphoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
The EBV-DNA amount in whole blood was useful for predicting tumor response, toxicity, and prognosis after SMILE chemotherapy for ENKL.
|
22675173 |
2012 |
|
Heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
The present subgroup analysis from the post-marketing surveillance SMILE Study aims to explore the efficacy and safety of tolvaptan across the HF subgroups (HFrEF, HFpEF, and HFmrEF).Patients with HF accompanied by fluid retention who received tolvaptan were enrolled.
|
31484861 |
2019 |
|
Congestive heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
The present subgroup analysis from the post-marketing surveillance SMILE Study aims to explore the efficacy and safety of tolvaptan across the HF subgroups (HFrEF, HFpEF, and HFmrEF).Patients with HF accompanied by fluid retention who received tolvaptan were enrolled.
|
31484861 |
2019 |
|
Heart failure
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublished Data of the Randomized Double-Blind SMILE-4 Study.
|
29667144 |
2018 |
|
Congestive heart failure
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublished Data of the Randomized Double-Blind SMILE-4 Study.
|
29667144 |
2018 |
|
Acute myocardial infarction
|
0.020 |
Biomarker
|
disease |
BEFREE |
The four SMILE studies demonstrated that early administration of zofenopril following acute myocardial infarction is prognostically beneficial compared to placebo or other angiotensin-converting enzyme (ACE) inhibitors.
|
28155333 |
2017 |
|
Acute myocardial infarction
|
0.020 |
Biomarker
|
disease |
BEFREE |
The SMILE-4 study showed that in patients with left ventricular dysfunction (LVD) after acute myocardial infarction, early treatment with zofenopril plus acetyl salicylic acid is associated with an improved 1-year survival, free from death or hospitalization for cardiovascular (CV) causes, as compared to ramipril plus acetyl salicylic acid.
|
28195948 |
2017 |
|
Lymphoma
|
0.020 |
Biomarker
|
group |
BEFREE |
P-glycoprotein is a product of the multidrug resistance (MDR1) gene, which is a major cause of the refractoriness of malignant lymphomas to conventional chemotherapeutic regimens containing anthracycline. l-asparaginase-containing regimens such as SMILE (steroid, methotrexate, ifosfamide, l-asparaginase, and etoposide) are effective for ENKL.
|
23768637 |
2013 |
|
Lymphoma
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Extranodal NK/T-cell lymphoma, nasal type (ENKL) is an Epstein-Barr virus (EBV)-associated lymphoma for which a new chemotherapeutic regimen called SMILE (steroid, methotrexate, ifosfamide, L-asparaginase, and etoposide) recently showed promising results.
|
22675173 |
2012 |
|
Dermoid Cyst
|
0.010 |
Biomarker
|
disease |
BEFREE |
To report a novel technique to treat superficial limbal dermoid by using the corneal intrastromal lenticules obtained from SMILE and to evaluate the initial clinical outcomes of lenticule patch graft for treatment of limbal dermoid.
|
31735992 |
2020 |
|
Astigmatism
|
0.010 |
Biomarker
|
disease |
BEFREE |
Clinical outcomes and vector analysis of astigmatism were reviewed and compared between wavefront-guided laser in situ keratomileusis (LASIK) (WFG group) (STAR S4 IR with iDesign aberrometer; Johnson & Johnson Vision Care, Inc., Santa Ana, CA), topography-guided LASIK (TOPO group) (Allegretto Wave Eye-Q laser; Alcon Laboratories, Inc., Fort Worth, TX), and small incision lenticule extraction (SMILE group) (VisuMax laser; Carl Zeiss Meditec AG, Jena, Germany).
|
31710370 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with <i>EGFR</i>-mutated non-small-cell lung cancer - A multicenter prospective SMILE study.
|
31417660 |
2019 |
|
ovarian neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeting HDAC4, HIF-1α and CREBZF may be considered in treatment of ovarian cancer with p53 and RAS mutations.
|
30867818 |
2019 |
|
Malignant neoplasm of ovary
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeting HDAC4, HIF-1α and CREBZF may be considered in treatment of ovarian cancer with p53 and RAS mutations.
|
30867818 |
2019 |
|
Liver regeneration disorder
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
In contrast, adeno-associated virus mediated overexpression of CREBZF in the liver inhibits the expression of cyclin gene family and attenuates liver regeneration in CCl<sub>4</sub> -treated mice.
|
31469186 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.010 |
Biomarker
|
disease |
BEFREE |
Targeting HDAC4, HIF-1α and CREBZF may be considered in treatment of ovarian cancer with p53 and RAS mutations.
|
30867818 |
2019 |
|
Adenoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Thus, we identified three miRNAs (hsa-miR-421, hsa-miR-29b-1-5p, and hsa-miR-27b-5p) with two mRNAs (FBXO11 and CREBZF) that might play an important role in the GC development from premalignant adenomas.
|
29725252 |
2018 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
Smartphone problem-solving and behavioural activation therapy to reduce fear of recurrence among patients with breast cancer (SMartphone Intervention to LEssen fear of cancer recurrence: SMILE project): protocol for a randomised controlled trial.
|
30413519 |
2018 |
|
Dry Eye Syndromes
|
0.010 |
Biomarker
|
disease |
BEFREE |
A new type of corneal refractive surgery, SMILE, which has less impact on corneal nerves, induces less postoperative dry eye, supporting the association between corneal denervation and postoperative dry eye.
|
30481814 |
2018 |
|
Epilepsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
To determine the effectiveness and cost-effectiveness of Self-Management education for people with poorly controlled epILEpsy [SMILE (UK)].
|
29717699 |
2018 |